Best Cancer Hospital in Indore

Oncology covers the diagnosis and treatment of cancer. Oncologists manage solid tumours across the breast, lung, gastrointestinal tract, head and neck, gynaecological, urological and musculoskeletal system, and haematological malignancies including leukaemia, lymphoma and myeloma. At CARE CHL Hospitals, Indore, medical, surgical and radiation oncology work as a single integrated programme.

Seek assessment for an unexplained lump, unintentional weight loss, persistent fatigue, a change in bowel or urinary habits, blood in urine or stool, a non-healing sore, hoarseness lasting more than three weeks and abnormal bleeding. Most of these have benign explanations but investigation is always preferable to watching and waiting.

CARE CHL Hospitals, Indore provides integrated medical, surgical and radiation oncology with multidisciplinary tumour team review, in-house molecular diagnostics, a dedicated chemotherapy unit, haemato-oncology with BMT coordination and palliative care built into the pathway.

We provide:

• Chemotherapy, targeted therapy and immunotherapy in the day-care unit
• Surgical oncology with minimally invasive approaches where appropriate 
• Bone marrow transplantation for eligible haematological malignancies
• Palliative care, nutritional support and pain management throughout treatment.

Yes early-stage cancer is where the widest range of curative options exists and where long-term remission is most achievable. Surgical resection, limited-field radiation and short-course chemotherapy can each achieve durable disease control in early-stage presentations, which is why screening and prompt specialist referral matter.

Yes both are available in the dedicated oncology day-care unit. Targeted therapy eligibility is determined by in-house biomarker testing (EGFR, ALK, HER2, BRAF, CDK4/6 and PD-L1) so treatment is matched to the tumour's molecular profile.

Common warning signs are:

• An unexplained lump
• Persistent fatigue without a clear cause
• Unintentional weight loss
• A change in bowel habits lasting more than a few weeks
• Blood in urine or stool
• A sore or ulcer that does not heal
• A skin lesion changing in size or colour
• Hoarseness or swallowing difficulty that has not resolved. 

Each needs assessment rather than observation.

Yes. All four are within the oncology programme at CARE CHL Hospitals, Indore. Breast cancer is managed based on hormone receptor and HER2 status. Lung cancer treatment is driven by histological type and molecular profile. Colorectal cancer is assessed for RAS and BRAF status. Prostate cancer is managed from detection through to metastatic disease within a multidisciplinary framework.

Medical oncology covers systemic treatments including chemotherapy, targeted therapy, immunotherapy and hormonal therapy. Surgical oncology manages tumour resection and operative staging. Radiation oncology delivers targeted radiation for local control. Most patients need input from more than one of these, and at CARE CHL Hospitals, Indore all three review complex cases at the tumour board together.

Key considerations are: whether a multidisciplinary tumour team reviews cases before treatment starts; whether molecular diagnostics are in-house; whether medical, surgical and radiation oncology are integrated; whether haemato-oncology is part of the service; whether palliative care is embedded rather than arranged separately; and whether second opinions are available without pressure to transfer care.

Yes. Oncological emergencies including febrile neutropaenia, spinal cord compression, superior vena cava syndrome and hypercalcaemia of malignancy are managed with specialist input at all hours. Patients on chemotherapy with fever or acute deterioration should attend the Emergency Department directly.

Advanced diagnostic tests are:

• Imaging like PET-CT, CT and MRI
• Ultrasound-guided and CT-guided biopsy with histopathology and immunohistochemistry
• Molecular profiling (EGFR, ALK, HER2, KRAS, BRAF, MSI, PD-L1)
• Serum tumour markers
• Bone marrow biopsy
• Flow cytometry and cytogenetics.

Yes. The haemato-oncology service manages acute and chronic leukaemia, Hodgkin and non-Hodgkin lymphoma, multiple myeloma and MDS, with chemotherapy, monoclonal antibody therapy and bone marrow transplant coordination for eligible patients.

Yes treatment plans are built around the individual patient. Tumour type, stage, molecular profile, performance status and the patient's own priorities all inform the decision. Tumour board review ensures collective specialist judgment. Molecular diagnostics determine targeted therapy eligibility. That is what personalised cancer care means in clinical practice.

Yes. Targeted therapy achieves prolonged remission with fewer side effects than conventional chemotherapy in many tumour types. Immunotherapy produces durable responses across several malignancies. Palliative care integrated from diagnosis (not only at the end of life) substantially improves symptom burden and functional status throughout treatment.

Yes. Laparoscopic and thoracoscopic oncological surgery are available for eligible patients, reducing operative morbidity when adjuvant chemotherapy or radiation is planned to follow. Resectability is reviewed at the multidisciplinary tumour team before any surgical commitment is made.

Treatments available are:

• Systemic therapy including chemotherapy, targeted agents, checkpoint immunotherapy and hormonal therapy
• Palliative radiation for local symptom control; palliative surgical procedures where clinically indicated
• A structured palliative care programme covering pain management, nutrition and psychological support.

CARE CHL Hospitals, Indore provides integrated oncology with in-house molecular diagnostics, a dedicated chemotherapy unit, haemato-oncology, BMT coordination and palliative care - accessible to patients from across Indore and the wider Madhya Pradesh region.

Yes. The oncology team reviews existing pathology and imaging and provides a clear, evidence-based view. There is no expectation that the patient will transfer care to CARE CHL Hospitals following a second opinion consultation.

Yes. PET-CT, ultrasound-guided and CT-guided biopsy, immunohistochemistry, molecular profiling and a full serum tumour marker panel are all in-house at CARE CHL Hospitals, Indore. Patients complete their cancer staging workup without being directed to multiple external facilities.

Yes. Antiemetics, growth factor support to reduce neutropaenic risk, mucositis management, radiation skin care and nutritional support during treatment are all provided. Side effects are monitored at each cycle and the regimen is adjusted where toxicity requires it.

Precautions include:

• Report fever above 38°C immediately
• Avoid close contact with people who have active infections during periods of immunosuppression
• Maintain nutrition and hydration
• Do not start new supplements or medications without checking with the oncology team
• Attend all scheduled monitoring appointments

Yes. Nutritional assessment, pain management across the full analgesic spectrum, psychological support and palliative care are embedded in the oncology programme at CARE CHL Hospitals, Indore - running alongside active cancer treatment from the point of diagnosis, not arranged separately by the patient.

Appointments can be made by calling CARE CHL Hospitals, Indore directly, through the online booking platform or by attending the outpatient department. Patients with a confirmed cancer diagnosis are prioritised to minimise time to first specialist contact. For oncological emergencies, attend the Emergency Department directly.

CARE CHL Hospitals, Indore covers the full cancer care pathway within a single integrated programme ranging from staging and tumour board review through chemotherapy, surgery and supportive care to long-term surveillance making it a comprehensive oncology destination for patients across Madhya Pradesh.